{"classes":[{"categories":[{"measurements":[{"comment":"The MTD was not found because we did not have enough participant participation.","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"MTD is defined as the number of participants experiencing a dose-limiting toxicity (DLT). A DLT is defined as Grade 4 or greater anemia or neutropenia exceeding 5 days duration, thrombocytopenia requiring transfusion, or Grade 3 or greater nonhematologic toxicity possibly, probably, or definitely related to the investigational therapy excluding alopecia during Cycle 1 of therapy.","groups":[{"description":"All participants in phase I dose level 1 and dose level -1.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At the end of first 14 day cycle at each dose level","title":"Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"mcg/kg"}